Clinical Trial: HBV Reactivation Prediction Model in Allo-HSCT

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07644026) titled 'HBV Reactivation Prediction Model in Allo-HSCT' on June 08.

Brief Summary: Hepatitis B virus (HBV) reactivation is a serious complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT), particularly in patients with resolved HBV infection (HBsAg-negative, anti-HBc-positive). The incidence ranges from 10% to 40%, and severe reactivation can lead to hepatitis flare, hepatic failure, and death.

Several risk factors have been identified: low recipient anti-HBs titre, donor anti-HBs negativity, recipient age >=50 years, chronic GVHD, and use of rituximab. However, no validated clinical prediction model exists for ...